Literature DB >> 11235990

Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells.

M Nakui1, A Ohta, M Sekimoto, M Sato, K Iwakabe, T Yahata, H Kitamura, T Koda, T Kawano, H Makuuchi, M Taniguchi, T Nishimura.   

Abstract

The combined therapeutic effect of natural killer T (NKT) cell ligand alpha-galactosylceramide (alpha-GalCer) and IL-12 against highly metastatic B16-BL6-HM melanoma cells was investigated. In comparison with a single administration of alpha-GalCer or IL-12, the combined treatment of tumor-bearing mice with alpha-GalCer plus IL-12 caused a super-induction of serum IFN-gamma levels, though alpha-GalCer-induced IL-4 production was rather inhibited. In parallel with the augmented IFN-gamma production, the natural killing activity against YAC-1 cells and syngeneic B16-BL6-HM melanoma was greatly augmented by the combined therapy. The major effector cells responsible for natural killing activity induced by alpha-GalCer plus IL-12 were enriched in both NK1.1+ TCRalphabeta+ NKT cells and NK1.1+ TCRalphabeta- NK cells. The preventing effect of alpha-GalCer or IL-12 alone against lung metastasis of B16-BL6-HM was also enhanced by the combination therapy. The antitumor activity of alpha-GalCer was totally abolished in NKT-deficient mice. However, IL-12-induced antitumor activity was not eliminated in NKT-deficient mice though it was inhibited by anti-asialo GM1 Ab treatment. These findings suggested that alpha-GalCer synergistically act with IL-12 to activate both NKT cells and NK cells, which may play a critical role in the strong prevention of distant tumor metastasis at early stages of tumor-bearing. These data will provide a novel tool for the prevention of tumor metastasis using NKT-specific ligands alpha-GalCer and IL-12.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11235990     DOI: 10.1023/a:1006715221088

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

1.  Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.

Authors:  N Singh; S Hong; D C Scherer; I Serizawa; N Burdin; M Kronenberg; Y Koezuka; L Van Kaer
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

2.  Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines.

Authors:  S Sad; R Marcotte; T R Mosmann
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

3.  Critical role of NK1+ T cells in IL-12-induced immune responses in vivo.

Authors:  T Kawamura; K Takeda; S K Mendiratta; H Kawamura; L Van Kaer; H Yagita; T Abo; K Okumura
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

4.  Involvement of IL-4-producing Vbeta8.2+ CD4+ CD62L- CD45RB- T cells in non-MHC gene-controlled predisposition toward skewing into T helper type-2 immunity in BALB/c mice.

Authors:  T Nishimura; K Santa; T Yahata; N Sato; A Ohta; Y Ohmi; T Sato; K Hozumi; S Habu
Journal:  J Immunol       Date:  1997-06-15       Impact factor: 5.422

5.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; H Sato; E Kondo; M Harada; H Koseki; T Nakayama; Y Tanaka; M Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  Stringent V beta requirement for the development of NK1.1+ T cell receptor-alpha/beta+ cells in mouse liver.

Authors:  T Ohteki; H R MacDonald
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

7.  Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12.

Authors:  W Hashimoto; K Takeda; R Anzai; K Ogasawara; H Sakihara; K Sugiura; S Seki; K Kumagai
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

8.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.

Authors:  J T Vetto; M Z Papa; M T Lotze; A E Chang; S A Rosenberg
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

9.  The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.

Authors:  H Kitamura; K Iwakabe; T Yahata; S Nishimura; A Ohta; Y Ohmi; M Sato; K Takeda; K Okumura; L Van Kaer; T Kawano; M Taniguchi; T Nishimura
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

10.  Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain.

Authors:  S Porcelli; C E Yockey; M B Brenner; S P Balk
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  13 in total

1.  Influence of whole peptidoglycan of bifidobacterium on cytotoxic effectors produced by mouse peritoneal macrophages.

Authors:  L S Wang; H M Zhu; D Y Zhou; Y L Wang; W D Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

Review 2.  Is cancer vaccination feasible at older age?

Authors:  Claudia Gravekamp; Arthee Jahangir
Journal:  Exp Gerontol       Date:  2014-02-06       Impact factor: 4.032

Review 3.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

Review 4.  The impact of aging on cancer vaccination.

Authors:  Claudia Gravekamp
Journal:  Curr Opin Immunol       Date:  2011-07-18       Impact factor: 7.486

Review 5.  Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.

Authors:  Gloria Delfanti; Paolo Dellabona; Giulia Casorati; Maya Fedeli
Journal:  Front Med (Lausanne)       Date:  2022-05-09

Review 6.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 7.  Aging and cancer vaccines.

Authors:  Claudia Gravekamp; Dinesh Chandra
Journal:  Crit Rev Oncog       Date:  2013

8.  Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.

Authors:  Ya-Jen Chang; Jing-Rong Huang; Yi-Chien Tsai; Jung-Tung Hung; Douglass Wu; Masakazu Fujio; Chi-Huey Wong; Alice L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-12       Impact factor: 11.205

Review 9.  Biosurfactants Produced by Marine Microorganisms with Therapeutic Applications.

Authors:  Eduardo J Gudiña; José A Teixeira; Lígia R Rodrigues
Journal:  Mar Drugs       Date:  2016-02-18       Impact factor: 5.118

10.  Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosylceramide in established murine cancer model.

Authors:  Hiroyasu Ito; Tatsuya Ando; Mitsuru Seishima
Journal:  Oncotarget       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.